Meduri G U, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A
Department of Medicine, University of Tennessee Medical Center, Memphis, USA.
Chest. 1995 Nov;108(5):1315-25. doi: 10.1378/chest.108.5.1315.
In late ARDS, a persistent and exaggerated inflammatory response causes recurrent injury to the alveolocapillary barrier and amplification of intra-alveolar fibroproliferation. When ARDS patients fail to improve, corticosteroid (CS) rescue treatment frequently leads to rapid improvements in lung function. We tested the hypothesis that response to CS treatment is related to suppressing the inflammatory response by comparing changes in lung function to inflammatory cytokine (IC) levels in the plasma and BAL.
Blood samples were obtained on days 1, 3, 5, and 7 of ARDS, and on days -5, -3, 0 (initiation of treatment), +3, +5, +7, +10, and +14 of CS treatment. Bilateral BAL was obtained on day 1 of ARDS, before administration of CS treatment, and at weekly intervals. We analyzed changes in IC levels during CS treatment in relation to improvements in lung injury score (LIS), indices of endothelial permeability, and final outcome. We also analyzed data to identify timing to a significant reduction in plasma IC levels and predictors of response.
Nine patients entered the study. CS treatment was initiated 15 +/- 9 days into ARDS. Improvement in LIS (> 1-point reduction) was rapid (< 7 days) in five, delayed (< 14 days) in two, and absent in two. Baseline plasma and BAL IC levels in study patients were similar to a previously reported comparison group of 12 ARDS nonsurvivors. No significant changes in plasma and BAL IC levels were observed before CS administration. Following initiation of CS treatment, significant reductions in plasma tumor necrosis factor-alpha and interleukin 6 (IL-6) levels were seen by day 7 in both rapid and delayed responders (p = 0.03). IL-1 beta was significantly reduced by day 5 (p = 0.04) in rapid responders and by day 10 (p = 0.03) in delayed responders. In responders, improvement in LIS and BAL albumin paralleled reduction in plasma and BAL IC levels. At initiation of treatment, rapid responders had significantly lower tumor necrosis factor-alpha and IL-6 levels. Nonresponders had a significantly higher plasma IL-6 level on days 1 to 3 of ARDS (p = 0.004) and lower ratio of arteriolar oxygen tension to inspired oxygen concentration at initiation of treatment (p < 0.01).
In patients with late ARDS and a low likelihood of survival, prolonged corticosteroid rescue treatment was associated with a reduction in plasma and BAL IC levels and parallel improvements in indices of endothelial permeability and LIS.
在晚期急性呼吸窘迫综合征(ARDS)中,持续且过度的炎症反应会导致肺泡毛细血管屏障反复受损以及肺泡内纤维增殖加剧。当ARDS患者病情无改善时,皮质类固醇(CS)挽救治疗常常能使肺功能迅速改善。我们通过比较肺功能变化与血浆及支气管肺泡灌洗(BAL)液中炎症细胞因子(IC)水平,来检验CS治疗反应与抑制炎症反应相关这一假设。
在ARDS的第1、3、5和7天,以及CS治疗的第-5、-3、0(治疗开始)、+3、+5、+7、+10和+14天采集血样。在ARDS第1天、CS治疗前以及每周进行双侧BAL。我们分析了CS治疗期间IC水平的变化与肺损伤评分(LIS)、内皮通透性指标及最终结局改善情况的关系。我们还分析数据以确定血浆IC水平显著降低的时间点及反应的预测因素。
9名患者进入研究。在ARDS发病15±9天开始CS治疗。5名患者的LIS改善(降低>1分)迅速(<7天),2名患者延迟(<14天),2名患者无改善。研究患者的基线血浆和BAL IC水平与先前报道的12名ARDS非幸存者比较组相似。在给予CS之前,未观察到血浆和BAL IC水平有显著变化。开始CS治疗后,快速反应者和延迟反应者在第7天时血浆肿瘤坏死因子-α和白细胞介素6(IL-6)水平均显著降低(p = 0.03)。快速反应者在第5天(p = 0.04)IL-1β显著降低,延迟反应者在第10天(p = 0.03)IL-1β显著降低。在反应者中,LIS和BAL白蛋白的改善与血浆和BAL IC水平的降低平行。治疗开始时,快速反应者的肿瘤坏死因子-α和IL-6水平显著较低。无反应者在ARDS第1至3天血浆IL-6水平显著较高(p = 0.004),且治疗开始时动脉血氧分压与吸入氧浓度的比值较低(p < 0.01)。
在晚期ARDS且生存可能性低的患者中,延长的皮质类固醇挽救治疗与血浆和BAL IC水平降低以及内皮通透性指标和LIS的平行改善相关。